2型糖尿病患者试验中的事件发生率。 - Suppr

Suppr

超能文献

Event rates in trials of patients with type 2 diabetes.

作者信息

Preiss David, Sattar Naveed, McMurray John J

出版信息

JAMA. 2010 Feb 24;303(8):732-3; author reply 733. doi: 10.1001/jama.2010.138.

DOI:10.1001/jama.2010.138

PMID:20179281

Abstract

摘要

相似文献

Event rates in trials of patients with type 2 diabetes.

JAMA. 2010 Feb 24;303(8):732-3; author reply 733. doi: 10.1001/jama.2010.138.

Variation in event rates in trials of patients with type 2 diabetes.

JAMA. 2009 Oct 21;302(15):1698-700. doi: 10.1001/jama.2009.1497.

Event rates in trials of patients with type 2 diabetes.

JAMA. 2010 Feb 24;303(8):732; author reply 733. doi: 10.1001/jama.2010.137.

Setting the RECORD Straight.

JAMA. 2010 Mar 24;303(12):1194-5. doi: 10.1001/jama.2010.333.

[Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].

MMW Fortschr Med. 2007 Aug 2;149(31-32):52-3.

No evidence for a reduction of myocardial infarctions by acarbose.

Eur Heart J. 2004 Jul;25(13):1179; author reply 1179-80. doi: 10.1016/j.ehj.2004.01.026.

Intensive glucose lowering treatment in type 2 diabetes.

BMJ. 2011 Jul 26;343:d4243. doi: 10.1136/bmj.d4243.

Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction.

JAMA. 2010 Aug 25;304(8):897-8. doi: 10.1001/jama.2010.1205.

[Is an intensive glycaemic control beneficial in diabetes type 2?].

Dtsch Med Wochenschr. 2011 Sep;136(39):1940. doi: 10.1055/s-0031-1286394. Epub 2011 Sep 22.

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

JAMA. 2007 Sep 12;298(10):1189-95. doi: 10.1001/jama.298.10.1189.

引用本文的文献

Mortality rates in trials of subjects with type 2 diabetes.

J Am Heart Assoc. 2012 Feb;1(1):8-15. doi: 10.1161/JAHA.111.000059. Epub 2012 Feb 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Event rates in trials of patients with type 2 diabetes.

JAMA. 2010 Feb 24;303(8):732-3; author reply 733. doi: 10.1001/jama.2010.138.

Variation in event rates in trials of patients with type 2 diabetes.

JAMA. 2009 Oct 21;302(15):1698-700. doi: 10.1001/jama.2009.1497.

Event rates in trials of patients with type 2 diabetes.

JAMA. 2010 Feb 24;303(8):732; author reply 733. doi: 10.1001/jama.2010.137.

Setting the RECORD Straight.

JAMA. 2010 Mar 24;303(12):1194-5. doi: 10.1001/jama.2010.333.

[Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].

MMW Fortschr Med. 2007 Aug 2;149(31-32):52-3.

No evidence for a reduction of myocardial infarctions by acarbose.

Eur Heart J. 2004 Jul;25(13):1179; author reply 1179-80. doi: 10.1016/j.ehj.2004.01.026.

Intensive glucose lowering treatment in type 2 diabetes.

BMJ. 2011 Jul 26;343:d4243. doi: 10.1136/bmj.d4243.

Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction.

JAMA. 2010 Aug 25;304(8):897-8. doi: 10.1001/jama.2010.1205.

[Is an intensive glycaemic control beneficial in diabetes type 2?].

Dtsch Med Wochenschr. 2011 Sep;136(39):1940. doi: 10.1055/s-0031-1286394. Epub 2011 Sep 22.

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

JAMA. 2007 Sep 12;298(10):1189-95. doi: 10.1001/jama.298.10.1189.

引用本文的文献

Mortality rates in trials of subjects with type 2 diabetes.

J Am Heart Assoc. 2012 Feb;1(1):8-15. doi: 10.1161/JAHA.111.000059. Epub 2012 Feb 20.